Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer

Hong, David S., Concin, Nicole, Vergote, Ignace, de Bono, Johann S., Slomovitz, Brian M, Drew, Yvette, Arkenau, Hendrik-Tobias, Machiels, Jean-Pascal, Spicer, James, Jones, Robert, Forster, Martin, Cornez, Nathalie, Gennigens, Christine, Johnson, Melissa L, Thistlethwaite, Fiona C, Rangwala, Reshma A, Ghatta, Srinivas, Windfeld, Kristian, Harris, Jeffrey R, Lassen, Ulrik Niels and Coleman, Robert L. 2019. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clinical Cancer Research 10.1158/1078-0432.CCR-19-2962
Item availability restricted.

[img] PDF - Accepted Post-Print Version
Restricted to Repository staff only until 3 December 2020 due to copyright restrictions.

Download (765kB)

Abstract

Purpose: Tissue factor (TF) is a potential target in cervical cancer as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody-drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase 1/2 study (NCT02001623). Experimental Design: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. Results: Of the 55 patients, 51% had received ≥2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab+doublet chemotherapy. 51% of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% (95% confidence interval [CI]: 13%−37%). Median duration of response (DOR) was 4.2 months (range: 1.0+−9.7); four patients responded for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%−43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%−35%), median DOR of 6.0 months (range: 1.0+−9.7), and 6-month PFS rate of 40% (95% CI: 24%−55%). TF expression was confirmed in most patients; no significant association with response was observed. Conclusions: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.

Item Type: Article
Date Type: Published Online
Status: In Press
Schools: Medicine
Publisher: American Association for Cancer Research
ISSN: 1078-0432
Date of First Compliant Deposit: 18 December 2019
Date of Acceptance: 26 November 2019
Last Modified: 15 Mar 2020 04:49
URI: http://orca.cf.ac.uk/id/eprint/127646

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics